Dyne Therapeutics appoints John Cox as President and CEO, succeeding Joshua Brumm

Dyne Therapeutics, Inc.

John Cox appointed President and CEO effective March 25, 2024; also elected Class I director.
Joshua Brumm resigns as CEO and from the Board; will serve as consultant for 12 months.
Cox receives $700K base salary, up to 60% annual bonus, and option for 679,853 shares.
Brumm gets separation: 12 months salary, COBRA, and partial equity acceleration.
Board adopts 2024 Inducement Equity Plan authorizing 900,000 shares for new hires.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joshua Brumm

Chief Executive Officer

DYN · Dyne Therapeutics, Inc.

Effective: 2024-03-25
Successor: John Cox
Filed: March 25, 2024, 7:59 PM ET

succeeding Joshua Brumm

Appointed

John Cox

Class I Director

DYN · Dyne Therapeutics, Inc.

Effective: 2024-03-25
Filed: March 25, 2024, 7:59 PM ET

Mr. Cox was elected as a Class I director

Appointed

John Cox

President and Chief Executive Officer

DYN · Dyne Therapeutics, Inc.

Effective: 2024-03-25
Filed: March 25, 2024, 7:59 PM ET

had appointed John Cox as President and Chief Executive Officer of the Company succeeding Joshua Brumm

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.85

Joshua Brumm departed as Chief Executive Officer at Dyne Therapeutics, Inc..

Action: succeeded
Role: Chief Executive Officer

Exact text from the filing

succeeding Joshua Brumm

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Cox was elected as Class I Director at Dyne Therapeutics, Inc..

Action: elected
Role: Class I Director

Exact text from the filing

Mr. Cox was elected as a Class I director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Cox was appointed as President and Chief Executive Officer at Dyne Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

had appointed John Cox as President and Chief Executive Officer of the Company succeeding Joshua Brumm

View on SEC.gov

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-075932

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.